

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/563193  
Applicant : Ludwig NEYSES  
Filed : 03/15/2006  
TC/A.U. : not known  
Examiner : not known  
Confirmation No. : not known

Docket No. : WO05002495US

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a copy of an Information Disclosure Statement by Applicant ("IDS") (Form PTO/SB/08A and 08B as required) together with copies of the cited documents. It is respectfully requested that the cited documents be considered by the Examiner and the IDS be initialed by the Examiner to indicate such consideration and that a copy of such be returned to Applicant(s).

Pursuant to 37 C.F.R. § 1.97, the submission of this IDS is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this IDS is material to patentability. This IDS is being submitted under:

37 C.F.R. §1.97(b)

- ☐ (1) – i.e. within 3 mo of filing date of national ap (other than under 1.53(d))
- ☒ (2) – i.e. within 3 mo of date of entry in national stage (international ap 1.491)
- ☐ (3) – i.e. before mailing of first Office Action on the merits
- ☐ (4) – i.e. before mailing of first Office Action after filing RCE under 1.114

37 C.F.R. §1.97(c) – i.e. after time period of 1.97(b) and before an action closing prosecution (mailing date of final action 1.113, NOA 1.311, etc.) and is accompanied by:

☐ (1) – one of the statements of 1.97(e) below; OR

☐ (2) – the fee set forth in 1.17(p) and enclosed.

37 C.F.R. §1.97(d) – i.e. after time period of 1.97(c) and IDS is filed on or before issue fee and is accompanied by:

☐ (1) – one of the statements of 1.97(e) below; AND (2) – the fee set forth in 1.17(p) and enclosed.

37 C.F.R. §1.97(e) statement:

☐ (1) That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ (2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,

Dated: 03/15/2006

 Digitally signed by Alan Heimlich  
DN: CN = Alan Heimlich,  
C = US, O = Heimlich Law

Alan Heimlich / Reg. No. 48808  
Customer No. 40418  
Tel: +1 408 253 3860



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/563193		
		Filing Date	03/15/2006		
		First Named Inventor	Ludwig NEYSES		
		Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	WO05002495US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SCHUH KAI ET AL : "Plasma membrane Ca <sup>2+</sup> ATPase 4 is required for sperm motility and male fertility" JOURNAL OF BIOLOGICAL CHEMISTRY, vol . 279, no . 27, 2 July 2004 (2004-07-02), pages 28220-28226, XP008036550 ISSN : 0021-9258	
		KANWAR U ET AL : "GOSSYPOL INHIBITION OF CA <sup>++</sup> UPTAKE AND CA <sup>++</sup> -ATPASE IN HUMAN EJACULATED SPERMATOZOAL PLASMA MEMBRANE VESICLES" CONTRACEPTION, GERON-X, INC ., LOS ALTOS, CA, US, vol . 39, no . 4, 1 April 1989 (1989-04-01), pages 431-445, XP000561575 ISSN : 0010-7824	
		BREITBART H ET AL : "THE ROLE OF CALCIUM AND CA <sup>2+</sup> -ATPASE IN MAINTAINING MOTILITY IN RAM SPERMATOZOA" JOURNAL OF BIOLOGICAL CHEMISTRY . (MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol . 260, no . 21, 25 September 1985 (1985-09-25), pages 11548-11553, XP001009929	
		PATNI ANIL K ET AL : "Role of intracellular calcium in the spermicidal action of 2',4'-dichlorobenzamil, a novel contact spermicide" JOURNAL OF PHARMACY AND PHARMACOLOGY, vol . 53, no . 10, October 2001 (2001-10), pages 1387-1392, XP008036557 ISSN : 0022-3573	
		SCHUH KAI ET AL : "The sarcolemmal calcium pump PMCA : An effector of platelet aggregation ." CIRCULATION, vol . 106, no . 19 Supplement, 5 November 2002 (2002-11-05), pages 11-79, XP008036566 & ABSTRACTS FROM SCIENTIFIC SESSIONS ; CHICAGO, IL, USA ; NOVEMBER 17-20, 2002 ISSN : 0009-7322	
		YANG Z ET AL : "Na <sup>+</sup> -Ca <sup>2+</sup> exchange activity is localized in the T-tubules of rat ventricular myocytes" CIRCULATION RESEARCH, vol . 91, no . 4, 23 August 2002 (2002-08-23), pages 315-322, XP008036552 ISSN : 0009-7330	

Examiner Signature	/Samira Jean-louis/	Date Considered	04/03/2009
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./